-
-
-
-
-
-
-
Vertex (VRTX) PT Raised to $450 at Oppenheimer
-
-
-
-
-
-
-
Vertex Receives CHMP Positive Opinion for the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVYâ„¢ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thal
-
-
-
-
-
-
-
Vertex to Announce Third Quarter 2023 Financial Results on November 6
-
-
-
-
-
-
-
Vertex Pharma (VRTX) Tops Q4 EPS by 26c; Guides FY Revenue
-
-
-
-
-
-
-
Catalyst Biosciences Reports Second Quarter 2022 Operating & Financial Results
-
-
-
-
-
-
-
Vertex (VRTX) is a Clean Revenue Growth Story, Pipeline is Discounted and Stock Remains Preferred - BMO Capital
-
-
-
-
-
-
-
Vertex to Announce Third-Quarter 2021 Financial Results on November 2
-
976,641 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All